MoneyWorks4Me

SMS Pharmaceuticals informs about AGM

27 Aug 2026 Evaluate
SMS Pharmaceuticals has informed that due to certain unavoidable circumstances, administrative and scheduling constraints, today the Board of Directors of the Company, have approved, change in the date of the 38th Annual General Meeting (“AGM”) of the Company and consequently the record date for determining the Members eligible to receive the dividend, and book closure dated were revised, through circulation. Accordingly, the revised schedule is as enclosed. 38th Annual General Meeting of the Company, for the financial year ended 31st March, 2026, shall now be held on Tuesday, 29th September, 2026, (instead of Wednesday, 23rd September, 2026) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”), in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India; The Register of Members and Share Transfer Books of the Company shall remain closed from Wednesday, 23rd September, 2026 to Tuesday, 29th September, 2026, (both days inclusive), for the purpose of the 38th AGM; The Company has fixed Tuesday, 22nd September, 2026 as the ‘Record Date’ (instead of Wednesday, 16th September, 2026) for determining the Members eligible to receive the dividend for the financial year 2025-26, if approved at the ensuing AGM and the same will be paid within the stipulated time period. All other items in earlier intimation dated 31st July, 2026 shall remain unchanged.

The above information is a part of company’s filings submitted to BSE.

SMS Pharmaceuticals Share Price

355.40 -7.35 (-2.03%)
28-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1920.10
Dr. Reddys Labs. 1177.80
Cipla 1418.00
Lupin 2175.00
Zydus Lifesciences 1187.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: